Home
overview

SAE Media Group’s 2nd Annual Conference
Transdermal and Microneedle Drug Delivery
January 23 - 24, 2023 | London, UK
-------------------------------------------------------------------------
SAE Media Group is proud to present the 2nd annual Transdermal and Microneedle Drug Delivery Conference, taking place on the 23rd to 24th January 2022.

SAE’s 2nd annual Transdermal and Microneedle Drug Delivery conference will explore advances in microneedle diagnostics through case studies and real-world examples, whilst engaging in modern strategies for topical and transdermal drug delivery. The two-day agenda offers you peer-to-peer networking with CEO’s, Senior Vice presidents, Directors of Delivery Technologies, Heads of Product Development and many more.

 Key considerations for the conference will be transdermal and microneedle systems as a mode of therapeutic drug delivery in combination with optimization of device design and development. Vaccine delivery will a significant aspect of this year’s agenda with a focus on microneedle delivery technologies as a mode for vaccine delivery, in the pursuit to increase vaccine stability and accessibility. An outlook of the transdermal space will also be reviewed, including future directions and next steps required to advance the current field and accelerate access for patients and end users.
 

  • Engage with senior industry opinion leaders presenting their experiences and case studies in modern strategies for topical and transdermal drug delivery.
  • Gain insights from key industry experts on transdermal and microneedle systems as tools for therapeutic drug delivery
  • Understand how to optimize design and manufacturing development of transdermal delivery technologies
  • Explore and benchmark against industry advances in microneedle diagnostics through case studies and real-world examples

 

 

  • Drug-Delivery Device Developers
  • Microneedle Device Developers
  • Transdermal Delivery Developers
  • Microarray Patch Developers
  • Medical Device Engineers
  • Primary Packaging Material Designers
  • Secondary Packagers
  • Smart Device Developers
  • Training Device Developers
  • Device-Safety Solution Providers
  • Drug Developers
  • Transdermal Drug Product Developers
  • Previous attendees include:
  •  

Abbott EPD; AbbVie; Anodyne Nanotech, Inc; Astra Zeneca; Bayer AG; Bayer Pharma; BD; Biomedical Advanced Research & Development Authority (BARDA); Cardiff University; CDER/FDA; FDA; Gavi; Georgia Institute of Technology; German Federal Institute for Drugs and Medical Devices (BfArM); GSK; GSK Vaccines; Ichnos Sciences; Kindeva; Kindeva Drug Delivery; LEO Pharma; LEO Pharma A/S; LTS Lohmann Therapie-Systeme AG; Marbl; Merck & co.; N/A; Novo Nordisk; PATH; QuadMedicine, Inc.; Queen's University Belfast; RAUMEDIC AG; Skinport SIA; Suzhou Reveda Medical; Swansea University; U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES; University Medical Pharmaceuticals; Vaxess Technologies; Vaxxas; Win Coat Corporation; Working in Tandem Ltd; World Health Organization; Zosano Pharma;

Conference programme

8:00 Registration & Coffee

9:00 Chairman's Opening Remarks

Sanjiv Sharma

Sanjiv Sharma, Senior Lecturer in Medical Engineering, Swansea University
View Bio

9:10 Making microneedle based transdermal and intradermal delivery smarter: a new perspective

Sanjiv Sharma

Sanjiv Sharma, Senior Lecturer in Medical Engineering, Swansea University
View Bio

  • Making microneedles smarter
  • Diagnostic microneedles
  • Closing the loop for personalised drug delivery
  • 9:50 Exploring modern strategies on topical and transdermal drug delivery

    Clemens Gunther

    Clemens Gunther, Director, Senior Expert Nonclinical Safety, Bayer AG
    View Bio

  • Understanding the difference between local, regional, systemic and targeted drug delivery
  • Nanoparticles and microneedles as current areas of interest for transdermal drug delivery
  • Bioequivalence concepts for systemic and topical therapy
  • 10:30 Morning Coffee

    11:00 Exploring Transdermal and microneedle systems as next generation vaccines

    Simona Gallorini

    Simona Gallorini, Expert Scientist in Advanced technologies, GSK Vaccines
    View Bio

  • Rational behind skin delivery for vaccine
  • Advantages and challenges of microneedle for vaccine delivery
  • Strategies to improve the efficacy of skin vaccine delivery
  • How to step forward
  • 11:40 Development of vaccine microneedle array patches (MAPs) for creating new market space

    Seong-O Choi

    Seong-O Choi, Chief Scientific Officer, QuadMedicine, Inc.
    View Bio

  • Microneedle array patch platforms for vaccine administration
  • Case study: development of hepatitis B vaccine MAP
  • Future directions for GMP manufacturing
     
  • 12:20 Networking Lunch

    13:20 Exploring the potential of vaccine microarray patches (MAPS) response to future pandemics

    Ajoy Chakrabarti

    Ajoy Chakrabarti, Portfolio & Platform Lead, Polio, Bill & Melinda Gates Foundation
    View Bio

  • Understanding the current status of MAP technology
  • Benefits of MAPS for addressing future pandemics
  • Potential approaches to developing, deploying and using MAPS in
    future pandemic scenarios
  • 14:00 Transforming the vaccine landscape with the development of self-applied vaccine patches

    Michael Schrader

    Michael Schrader, Co-Founder & CEO, Vaxess Technologies
    View Bio

  • Exploring MIMIIX technology for vaccine administration
  • Translation from R&D to GMP clinical manufacturing
  • Key considerations from recent clinical data
  • 14:40 Afternoon Tea

    15:10 Enhancing vaccine performance through next generation vaccine technologies

    Megan Polidano

    Megan Polidano, Head of Regulatory Affairs, Vaxxas
    View Bio

  • Exploring HD-MAP technology for vaccine administration
  • Learnings from recent usability and accessibility studies z
  • Advantages of needle-free vaccine delivery
  • 15:50 Exploring MAPs as a novel delivery mechanism beyond typical syringe images

    Jeffrey Blue

    Jeffrey Blue, Executive Director of Vaccine Drug Product Development and New Technologies, Merck
    View Bio

  • Assessing the drug and vaccine viability within Microneedle delivery technologies
  • Expanding on drug dosage efficiencies
  • Case study: development of microneedles for the use of microarray patches and vaccine delivery systems
  • 15:50 The potential role of microarray patches in vaccine delivery

    16:30 Chairman’s Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    9:10 Exploring transdermal patches as a delivery method of therapeutic biologics

    Jake Lombardo

    Jake Lombardo, Co-Founder & CEO, Anodyne Nanotech, Inc
    View Bio

  • Understanding manufacturing considerations for microneedle
    technologies
  • Reviewing increased drug loading capacity of microneedle patches
    and opportunities beyond vaccine delivery
  • Addressing challenges of transdermal patches in the treatment of
    chronic disease
  • 9:50 Redefining the treatment landscape for cancer with transdermal drug delivery technologies

    Jamie Oliver

    Jamie Oliver, Chief Medical Officer, Starton Therapeutics
    View Bio

  • Review an animal efficacy and safety model developed to emulate
    transdermal delivery of an oncology small molecule
  • Translation of oral doses to continuous blood level targets associated
    with efficacy
  • Case study: key learnings from clinical and pre-clinical data
  • 10:30 Morning Coffee

    11:00 Improving existing transdermal technologies to reduce the liability profile of abusable medications

    Gareth Sheridan

    Gareth Sheridan, CEO, Nutriband Inc
    View Bio

  • Delving into the development of transdermal drug delivery systems
  • Case study: transdermal patches in the treatment of chronic pain
  • Future directions for transdermal delivery technologies
     
  • 11:40 Panel Discussion: Reviewing microneedle technolgies as a novel therapeutic tool for drug delivery

  • Discussing the benefits of microneedle patches and transdermal
    delivery systems
  • Understanding the challenges associated with microneedle
    technologies
  • Dissecting the latest trends in microneedle drug delivery
  • James  Birchall

    James Birchall, Professor of Pharmaceutical Sciences and Deputy Head of School, Cardiff University
    View Bio

    Michael Schrader

    Michael Schrader, Co-Founder & CEO, Vaxess Technologies
    View Bio

    Jake Lombardo

    Jake Lombardo, Co-Founder & CEO, Anodyne Nanotech, Inc
    View Bio

    Gareth Sheridan

    Gareth Sheridan, CEO, Nutriband Inc
    View Bio

    12:20 Networking Lunch

    13:20 De-risking development of transdermal and microneedle drug and vaccine delivery technologies

    14:00 Strategic Partnerships for Microarray Patch Development

    Tanima Sinha

    Tanima Sinha, Lead Interdisciplinary Scientist, HHS/ASPR/BARDA
    View Bio

  • Brief History of BARDA
  • BARDA’s interest alternative routes of administration (oral, intranasal, MAPs)
  • 2019 MAP/Alt Administration RFI and outcomes
  • BARDA’s 5-year strategic plan and next steps for MAPs
  •  

    14:40 Afternoon Tea

    15:10 Key challenges associated with development of microneedle technologies

    Muhammet Avcil

    Muhammet Avcil, Managing Director, Imperial BioScience
    View Bio

  • Assessing the key drivers of microneedle drug delivery
  • Reviewing microneedles as a therapeutic tool for Acne and scarring
  • Exploring the manufacturing requirements to bring microneedle
    technologies to market
  • 15:50 Microneedle array Patch (maP) delivery of vaccines vs. drug/Biologic aPi

    Tycho Speaker

    Tycho Speaker, Director, Drug Delivery and Biomaterials, AbbVie
    View Bio

  • Critical learnings from COVID pandemic
  • Key distinctions in User Needs
  • The novelty trap: “new” vs “improved”
  • 16:30 Chairman’s Closing Remarks and Close of Day Two

    +

    FEATURED SPEAKERS

    Ajoy Chakrabarti

    Ajoy Chakrabarti

    Portfolio & Platform Lead, Polio, Bill & Melinda Gates Foundation
    Clemens Gunther

    Clemens Gunther

    Director, Senior Expert Nonclinical Safety, Bayer AG
    Gareth Sheridan

    Gareth Sheridan

    CEO, Nutriband Inc
    Jake Lombardo

    Jake Lombardo

    Co-Founder & CEO, Anodyne Nanotech, Inc
    James  Birchall

    James Birchall

    Professor of Pharmaceutical Sciences and Deputy Head of School, Cardiff University
    Jamie Oliver

    Jamie Oliver

    Chief Medical Officer, Starton Therapeutics
    Jeffrey Blue

    Jeffrey Blue

    Executive Director of Vaccine Drug Product Development and New Technologies, Merck
    Megan Polidano

    Megan Polidano

    Head of Regulatory Affairs, Vaxxas
    Michael Schrader

    Michael Schrader

    Co-Founder & CEO, Vaxess Technologies
    Muhammet Avcil

    Muhammet Avcil

    Managing Director, Imperial BioScience
    Sanjiv Sharma

    Sanjiv Sharma

    Senior Lecturer in Medical Engineering, Swansea University
    Seong-O Choi

    Seong-O Choi

    Chief Scientific Officer, QuadMedicine, Inc.
    Simona Gallorini

    Simona Gallorini

    Expert Scientist in Advanced technologies, GSK Vaccines
    Tanima Sinha

    Tanima Sinha

    Lead Interdisciplinary Scientist, HHS/ASPR/BARDA
    Tycho Speaker

    Tycho Speaker

    Director, Drug Delivery and Biomaterials, AbbVie

    Ajoy Chakrabarti

    Portfolio & Platform Lead, Polio, Bill & Melinda Gates Foundation
    Ajoy Chakrabarti

    Ajoy Chakrabarti got his undergraduate degree in Biochemistry from Carleton University, PhD (Biochemistry) from the University of British Columbia and MBA from Cornell University. He has over 25 years of diverse product development experience in both pharmaceutical and biotechnology companies. He joined the Gates Foundation (BMGF) in 2016, working across multiple polio vaccine programs to provide strategic guidance and product development expertise as part of the global effort to eradicate polio. He has lead efforts to create Intervention Target Product Profiles for COVID-19 vaccines and therapeutics, as well as coordinating multiple COVAX CMC workshops in 2020-2021. Prior to joining BMGF, he spent eight years leading cross-functional product development teams working on anthrax therapeutics and vaccines, as well as nerve agent antidotes at Emergent BioSolutions. His experience at the Vaccine Research Center (NIH) and Bristol-Myers Squibb (1999-2008) included working in product development, marketing, portfolio management, decision analysis and forecasting.

    Clemens Gunther

    Director, Senior Expert Nonclinical Safety, Bayer AG
    Clemens Gunther

    Dr. Clemens Günther received his diploma in biology and doctorate for natural sciences from the Free University, Berlin-Germany. His thesis was on the subject of in vitro and in vivo investigations on the percutaneous absorption of estrogens and progestins as a basis for the development of a transdermal therapeutic system.


    Dr. Clemens Günther started his professional career in 1990 at Schering AG, Berlin-Germany. From 2007 to 2013, he was Director and Head of Global Preclinical Development at Intendis GmbH, branded later-on as Bayer Dermatology. In this position, he was responsible for Nonclinical Safety for the marketed product portfolio of Bayer Dermatology as well as the global preclinical development strategy including human DMPK for development and life cycle management projects.


    After integration of Intendis into Bayer in 2013, he became Director Nonclinical Safety Consumer Care and later-on Senior Expert Nonclinical Safety within the Division of Bayer Pharmaceuticals.
    Meanwhile Dr. Clemens Günther has gained about 35 years experience in drug development. He has been involved in nonclinical development and regulatory toxicology of small molecules, biologics, medical devices and drug device combination products.
     

    Gareth Sheridan

    CEO, Nutriband Inc
    Gareth Sheridan

    Gareth Sheridan is an award-winning entrepreneur, businessman and founder of Nutriband inc. Mr. Sheridan was Ireland’s ‘Young Entrepreneur of the Year’ in 2014 for establishing Nutriband and with it Nutriband was awarded Ireland’s ‘Best New Product 2014’. From starting a company derived from his thesis idea in University, Gareth went on to build the now NASDAQ listed Nutriband Inc who's core focus is to revolutionize the safety profile of opioid based transdermal pain treatments through its patented AVERSA abuse deterrent technology.

    Jake Lombardo

    Co-Founder & CEO, Anodyne Nanotech, Inc
    Jake Lombardo

    Jake has a unique combination of biomedical engineering experience and entrepreneurial acumen. He holds a B.S. of Biomedical Engineering from Union College and an M.Sc. of Innovation and Management from Tufts University. He couples this with leadership qualities developed over a lifetime of team sports to help set the direction of Anodyne.

    James Birchall

    Professor of Pharmaceutical Sciences and Deputy Head of School, Cardiff University
    James  Birchall

    James Birchall is Professor of Pharmaceutical Sciences and Deputy Head of the School of Pharmacy and Pharmaceutical Sciences, Cardiff University. Professor Birchall graduated from Bath University in 1993 and completed his PhD researching drug and DNA delivery systems in 1998 (Cardiff University). Current research includes pulmonary drug delivery and microneedle delivery of molecules, macromolecules, vaccines, auto-antigens and cells into skin for therapeutic, immunisation or immunotherapy applications.

    Professor Birchall has acted as Associate Editor of Critical Reviews in Therapeutic Drug Carrier Systems, a member of the Editorial Board of Expert Review of Medical Devices, a temporary advisor to the WHO and an expert advisor to the British Pharmacopoeia and conducted research funded by the EU, DFID, Bill and Melinda Gates Foundation, NIH, Wellcome Trust, EPSRC, MRC, Welsh Government, Royal Society, Innovate UK and various charities and pharmaceutical companies.
     

    Jamie Oliver

    Chief Medical Officer, Starton Therapeutics
    Jamie Oliver

    Drug development experience spanning 12 years in clinical academia and 28 years in both the public and private sectors of the biotechnology/pharmaceutical industry and contract research organizations serving in roles including Chief Executive Officer, Chief Medical Officer, Chief Operating Officer, Managing Director European and Asian Operations, and Chief Science Officer. Authored more than 60 IND applications and participated in the clinical programs for the approval of 7 New Drug Applications. Served as a collaborative scientist with the Centers for Disease Control hospital infections program and authored numerous manuscripts and presentations in immunology and cancer therapy.

    Jeffrey Blue

    Executive Director of Vaccine Drug Product Development and New Technologies, Merck
    Jeffrey Blue

     Jeffrey T. Blue has been with Merck more than 28 years. Through his career, Jeff has led the Vaccine Drug Product Development and New Technologies Department. Jeff’s department is responsible for the development of both in line and pipeline programs and spans both early and late-stage vaccine development. Jeff has supported live virus, oncolytic, subunit, conjugate, and mRNA vaccines. His department is responsible for technology transfer of the drug product formulation and process to the final commercial sites. In addition to pipeline support, his department is also responsible for supporting novel innovative technologies for drug product development including new drying technologies, novel adjuvants, and alternative delivery for vaccines and biologics (i.e., Patch technology (MAPs), ID and oral delivery, pulsatile and controlled release formulations, Lyospheres etc.).

    Through his leadership, the innovative technologies are being advanced to clinical development and recently gained manufacturing support for implementation into Merck’s vaccine pipeline. He has published multiple book chapters and various articles on vaccine drug product development and lyophilization. Over the course of his career within Merck, he has championed the development and successful launch of Varivax®, Zostavax®, and ProQuad® vaccines. He has also played an integral role in the development of the Ebola Zaire Vaccine that Merck has recently licensed (Ervebo®). Jeff has been a key leader on multiple cross-functional teams, engaged in key integration teams for vaccine strategy, is involved in multiple due diligence activities and continues to champion external collaborations to advance Merck’s vaccine pipeline.


     

    Megan Polidano

    Head of Regulatory Affairs, Vaxxas
    Megan Polidano

    Dr Polidano has worked in the biotechnology and pharmaceutical industry since 2003. Commencing her regulatory affairs career in 2007, Megan has worked on novel vaccine technologies and was responsible for managing the registration of seasonal influenza vaccine across Europe. She has spent time working as a consultant, responsible for the development of regulatory strategy, maintenance of product registration and for registering new medicines and medical devices across a broad range of therapeutic areas and in many countries. Megan has held senior regulatory roles in both pharmaceutical and medical device industries and joined Vaxxas as the head of regulatory affairs in March 2021.

    Michael Schrader

    Co-Founder & CEO, Vaxess Technologies
    Michael Schrader

    Michael Schrader is the CEO of Vaxess, clinical-stage company bringing healthcare out of the clinic and into patients’ lives with the MIMIX Smart Release patch platform. The company has a pipeline of vaccines and biologics under development, including the first influenza vaccine intended for home-based administration. Vaxess is headquartered in Cambridge, MA and has a GMP manufacturing facility in Woburn, MA. The company has raised more than $60M in grant and VC funding from groups such as The MIT Engine, BARDA, DARPA, NIH, NSF, and The Gates Foundation. Michael has served as an advisor to several startups including Ally Therapeutics and Adeo Health Sciences. He also serves as an Expert In Residence at the Harvard Office of Technology Development and as a Key Advisory Board Member for the Harvard Blavatnik Fellowship program. Prior to Vaxess, Michael spent time at Google and Honda where he helped bring a range of products to market and earned more than fifteen patents. Michael received his B.S. in Mechanical Engineering from Purdue University and his M.B.A. from Harvard.

    Muhammet Avcil

    Managing Director, Imperial BioScience
    Muhammet Avcil

    Dr Muhammet Avcil gained his honours degree in Chemistry and an MSc in Molecular Synthesis (Organic Syntheses) from the University of Sussex. After his MSc, He worked as a Research Assistant at the University of Sussex. He conducted his PhD research at the University of Sussex and Imperial College London. He has over 17 years of experience in biotechnology, drug discovery and development, working at universities and senior management positions in various institutions. He is a key figure in the management and strategic development of Imperial Bioscience and continues to get involved in the research and development of the company.

    Sanjiv Sharma

    Senior Lecturer in Medical Engineering, Swansea University
    Sanjiv Sharma

    Dr Sanjiv Sharma received his PhD on the development of analytical methods for determination of certain pharmaceuticals and their metabolites using miniaturised separation system in 2001. On completion of his fellowship he joined the Institute of Biomedical Engineering, Imperial College London to work with Professor Tony Cass in the area of Bionanotechnology and Biosensors. Here he developed minimally invasive microneedles, from photolithographic fabrication to high throughput fabrication, taking these microneedles from the lab to the clinic . Sanjiv was involved in a NIHR (i4i) funded research project involving clinical studies in healthy volunteers and participants with T1D with renowned Endocrinologist Clinicians; Professor Desmond Johnston and Professor Nick Oliver. He has published over 50 research articles and has patents filed in Germany, UK and the United States.
    Sanjiv is currently a Senior Lecturer in Medical Engineering in the College of Engineering at Swansea University. At Swansea, he is working on therapeutic drug delivery and diagnostic (theranostic) applications of polymeric microneedles.
     

    Seong-O Choi

    Chief Scientific Officer, QuadMedicine, Inc.
    Seong-O Choi

    <p>&lt;p&gt;Seong-O Choi is the CSO of QuadMedicine, a clinical-stage company developing microneedle platforms for medical and pharmaceutical applications. Seong-O has over 20 years of research experience in microfabrication and drug delivery systems, particularly in microneedles. Prior to joining QuadMedicine, Seong-O was a professor at Kansas State University, College of Veterinary Medicine, and a postdoctoral fellow/research engineer at the Georgia Institute of Technology, School of Chemical and Biomolecular Engineering. Seong-O has led numerous microneedle projects, including vaccination against hepatitis B, influenza, HPV, and smallpox. Seong-O received his B.S. degree in Physics from Yonsei University (Seoul, Korea), M.S. degree in Biomedical Engineering from the University of Southern California, and M.S. and Ph.D. degrees in Electrical and Computer Engineering from the Georgia Institute of Technology.&lt;/p&gt;</p>

    Simona Gallorini

    Expert Scientist in Advanced technologies, GSK Vaccines
    Simona Gallorini

    Simona Gallorini is an Expert Scientist in Advanced Technologies in the Drug Product department of Technical Research and Development at GSK Vaccines organization. She has completed his PhD in the immunology field at the University of Bologna and postdoctoral studies from Formulation and Delivery department at Novartis company. She worked in different projects from the ideation and execution at a discovery stage to clinical vaccine development. She has a sound scientific expertise in technological platforms both for injectable formulations and alternative delivery which led to the publication of several patents and papers in reputed journals.

    Tanima Sinha

    Lead Interdisciplinary Scientist, HHS/ASPR/BARDA
    Tanima Sinha

    Since Sept 2008, Tanima Sinha has been Lead Interdisciplinary Scientist in the Influenza and Emerging Infectious Disease Division, Vaccines Branch within BARDA ,where she is responsible for managing several high value contracts with industry to further develop promising influenza (pre-pandemic and seasonal) and Zika vaccine candidates by providing technical and scientific direction along with regulatory and budgetary oversight; also nonclinical task orders in support of SARS-CoV-2 and Zika virus medical countermeasure development efforts. Tanima is championing the alternative routes of administration program (microarray patch technology) in hopes of providing an alternative to traditional needle/syringe administration of vaccines, which may provide a more robust/durable immune response and perhaps address logistical issues of medical countermeasure distribution to more patients across the US and around the world.

    Tycho Speaker

    Director, Drug Delivery and Biomaterials, AbbVie
    Tycho Speaker

    Tycho Speaker is currently Director, Drug Delivery and Biomaterials at AbbVie. He holds a doctorate in physical chemistry, which is the basis for a career spanning a variety of manufacturing and formulation roles. Work toward treatment of a rare skin disorder (Pachyonychia Congenita) included the development of a novel dissolvable microneedle technology, among a range of other patents and innovations in various stages of commercialization.

    Sponsors

    Exhibitors

    Supporters

    VENUE

    Copthorne Tara Hotel

    Scarsdale Place, Kensington, London, United Kingdom

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    A number of our clients have been approached by third party organisations offering to book hotel rooms. We would advise that you do not book through them as they are not representing the SMi Group. SMi Group books all hotel rooms directly. If you are approached by a third party organisation then please contact us before making any bookings. If you have already booked a hotel room using a third party organisation, we would highly recommend contacting the hotel you were booked into to ensure a booking has been made for you. We would also advise you to please check the terms and conditions of the booking carefully.
    HOTEL BOOKING FORM

    Past Speaker Presentation - Mark Prausnitz – Georgia Institute of Technology

    Download

    Past Speaker Presentation - Tycho Speaker – AbbVie

    Download

    Past Speaker Presentation - Kerrie DeMacro – BARDA

    Download

    Past Speaker Presentation - Courtney Jarrahian – PATH

    Download

    Past Speaker Presentation - Caroline Strasinger – FDA

    Download

    Conference Brochure

    Download

    Full Agenda

    Download

    Short Agenda

    Download

    Speaker Biographies

    Download

    Chair Invitation Letter

    Download

    Sponsors


    QuadMedicine

    Sponsors
    https://www.quadmedicine.com

    WE CREATE BETTER TREATMENT TECHNOLOGY TO MAKE OUR LIVES HEALTHIER AND EASIER.

    QuadMedicine is a CDO company, presenting a medical microneedle platform upon request from pharmaceutical companies.

    We have built our own sophisticated microneedle production technology based on equipment and tool design capabilities.

    Also, QuadMedicine is specialized in formulation technology and drug coating technology with minimal drug loss.

    We can enhance drug stability and efficacy during manufacturing and storage.

    Above all, QuadMedicine is the first company in the world to establish a microneedle production facility that meets the requirements for vaccine manufacturing for clinical trials. In this facility, most vaccines and synthetic drugs can be handled.


    Exhibitors


    Raphas

    Exhibitors
    http://www.raphas.com/

    RAPHAS own patented technology (DEN, Drop Extension) can be developed into various products in any field needing delivery of active ingredients through the skin. Raphas’ DEN manufacturing technology has been already launched in the derma cosmetics market, and its competitiveness has been increased by verifying its convenience and stability. Furthermore, Raphas built up automatic inline equipment for mass production of DEN microneedle patch and is conducting further development with its partners in order to apply it to medical devices, specialized drugs, and patch vaccines. Raphas has conducted various human application tests such as clinical efficacy and skin irritation tests to prove the safety and efficacy of all commercial products. Raphas has entered into partnership with vaccine players based on its DEN manufacturing technology and is conducting joint collaboration with the aim of developing new patch vaccines. It is Raphas’ dream to develop the patch typed vaccine using our technology to bring vaccines and hope to children in countries with the greatest needs.



    Raumedic

    Exhibitors
    http://www.raumedic.com

    Together with its customers, the medical technology company is breaking new ground to improve the diagnosis and treatment of diseases. In doing so, Raumedic focuses on polymer-based solutions for medical and pharmaceutical applications, as well as on products for intensive care. Raumedic has a global presence and a headcount of approximately 1,000. In its core markets of Europe and North America, the company manufactures using its own clean room production facilities.

    Media Partners


    evvnt Ltd

    Supporters
    http://www.evvnt.com

    evvnt enables people all over the world to fill their events utilising the most effective event listing sites on the web. Every minute, with little more than a click, more events and conferences appear in listings, in search engines and on mobile - discoverable by both category and location. With next to no effort customers of evvnt get better attendance, while consumers find events they previously had no idea existed. To date customers in 70 countries worldwide have submitted over 500,000 thousand event listings, created over 300,000 live links, and generated 1 million clicks to ticketing and registration pages. Learn more at www.evvnt.com


    Pharmacircle

    Supporters
    http://www.pharmacircle.com

    PharmaCircle is an innovative knowledge management company serving the current and future global leaders in the Pharmaceutical and Biotechnology related industries. PharmaCircle is a one stop information and analysis source for pipeline, products, clinical trials, drug delivery technologies, deals and acquisitions, company financials, venture capital investments, product sales, pharmaceutical services, news, patents and more….


    World Pharma News

    Supporters
    http://www.worldpharmanews.com/



    EIN News

    Supporters
    http://www.einnews.com

    EIN News is the world leader in industry focused online news monitoring. Thousands of leading companies, institutions and global professionals from business, industry, and government rely on EIN News as an indispensable resource. Our systems continuously scan the web, indexing news from thousands of worldwide sources. The news you need is then organized by advanced software systems managed by a team of professional news editors. Everything we do is focused on streamlining your news searches and research in order to save you time and money.


    Mednous

    Supporters
    http://www.MedNous.com

    MedNous is a print publication and website about medical innovation in Europe. It carries exclusive interviews with companies that are at the forefront of medical technology, as well as contributor articles from prominent practitioners. Our mission is to identify significant advances in medicine and to explain how this innovation is being commercialised. In doing so, we talk to venture capitalists about what products and platforms they are supporting. We report on how regulators cope with the accelerating pace of innovation. And we regularly cover the latest developments in the discovery and development of new medical concepts in the area of antibodies, vaccines, small molecules, regenerative medicine and nanomedicines. MedNous combines the English word for medicine with the Greek word for intellect. And those with nous are readers of our publication. Visit our website: www.mednous.com


    Pharma Journalist

    Supporters
    http://www.pharmajournalist.com

    Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry. Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry. Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.


    ASD MEDIA

    Supporters
    http://www.asd-network.com

    Professionals in the Aerospace & Defence market use the ASD Media internet platforms to:
    • Be informed on the latest market developments; www.asd-network.com
    • Find the latest business news; www.asd-network.com
    • Find the upcoming events; www.asd-network.com
    • Find companies and organizations; www.asdsource.com
    • Distribute news globally. www.asdwire.com
    The ASD Media platforms are well known and used intensively, your company is able to benefit from these large numbers of users. Be informed with ASD-Network; Create exposure for your company with ASDSource, distribute your news with ASDWire or advertise with us, build your brand and increase traffic to your company’s website.

    For more detailed information please contact with: ASD MEDIA
    Stefan.koopman@asdmedia.nl


    pharmaphorum

    Supporters
    http://www.pharmaphorum.com

    pharmaphorum drives innovation within the pharmaceutical industry, by bringing healthcare together through a suite of media services that help produce and disseminate thought leadership, combined with an online platform for communicating messages to a global audience.Visit www.pharmaphorum.com


    On Drug Delivery

    Supporters
    http://www.ondrugdelivery.com/subscribe

    ONdrugDelivery provides 30,000 readers throughout global pharma/biopharma, with the latest, most pertinent industry information and intelligence about the drug delivery-related ideas, technologies, services and products the sector is developing. Established in 2004, and trusted throughout the industry for its high quality contributions from leading drug delivery experts, ONdrugDelivery is a must for pharma / biotech industry professionals who need to know what’s going on in drug delivery. Subscribe online today to the print or free digital edition: www.ondrugdelivery.com/subscribe.


    10 times

    Supporters
    http://10times.com

    10Times connect professionals with right information & people at the right place and time. Our name defines our audience & vision: Help Business Professionals grow. Events bringing together the right ingredients to generate value for the target audience. Over 2 million professional events are hosted for various topic, attracting over a billion knowledge audience around the world. We aim to ensure these events reach the right audience.


    Pharmiweb

    Supporters
    http://www.pharmiweb.com

    Established in October 2003, PharmiWeb Solutions is an energetic, innovative provider of web-based solutions for the pharmaceutical sector, with customers such as AstraZeneca, Roche, Servier Laboratories, and Merck With solutions in three key areas: Online Publishing, e-Business and Mobile Computing, we deliver connectivity – between people and applications – unlocking islands of data and knowledge. We own some of the sector’s most innovative Online Publications: PharmiWeb.com, HospitalPharma.com and Detail-Direct.com. We are actively developing solutions for Mobile Computing platforms. For example, our PharmiTabTM e-pharmacy solution runs real-time patient data and prescribing transactions in a busy hospital environment, on a TabletPC, wireless client/server platform. e-Business solutions range from e-Detailing, to Online Market Research, all designed to increase reach, increase sales, and to reduce administration and costs.


    Technology Networks

    Supporters
    http://go.technologynetworks.com/subscribe-to-newsletters

    Founded in 2000, Technology Networks is established as the leading news provider for life science and drug discovery professionals. In addition, we provide unique content including webcasts, videos, application notes and posters from recent conferences. Our portfolio now includes around 30 focussed scientific communities, all of which are accessible free of charge within TechnologyNetworks.com


    Pharmaceutical Technology

    Supporters
    http://www.pharmaceutical-technology.com

    Pharmaceutical-technology.com is the only website focusing specifically on issues relevant to pharmaceutical professionals working with technology, be it development, engineering, IT or production. Pharmaceutical-technology.com brings you the latest in industry projects and updates, along with the news, views and trends that leading professionals – from senior executives to manufacturing managers and heads of procurement – require to stay on top of their field.


    Drug Discovery Today

    Supporters
    http://www.drugdiscoverytoday.com/

    Drug Discovery Today covers the whole of the preclinical drug discovery process. The reviews are cutting edge, written by experts in their respective fields and cover all aspects of drug discovery from genomic and proteomic approaches, computational drug design, medicinal chemistry and the translation of these sciences to therapies.


    World Pharma Today

    Supporters
    http://www.worldpharmatoday.com


    SAVE TO


    Outlook Calendar  OUTLOOK CALENDAR
    Google Calendar  GOOGLE CALENDAR
    ICal Calendar  ICAL CALENDAR
    Yahoo! Calendar  YAHOO! CALENDAR

    Copthorne Tara Hotel

    Scarsdale Place
    Kensington
    London W8 5SR
    United Kingdom

    Copthorne Tara Hotel

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SAE Media Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@saemediagroup.com

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SAE Media Group

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SAE Media Group , Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smgconferences.com Email: events@saemediagroup.com
    Registered in England - SMi Group Ltd trading as SAE Media Group




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SAE Media Group.
    Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data@smgconferences.com.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out